News and events

All Press Releases

2021

Nicox Provides Third Quarter 2021 Business and Financial Highlights October 19, 2021
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase October 13, 2021
Nicox Launches New Corporate & Investor Website October 4, 2021
Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model September 29, 2021
Nicox First Half 2021 Financial Results and Business Update September 27, 2021
Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial September 24, 2021
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update 16 July 2021
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board 13 July 2021
Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement 05 July 2021
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial 02 July 2021
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial 01 July 2021
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates 25 June 2021
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021 24 June 2021
Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial 01 June 2021
Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico 5 May 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar 4 May 2021
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod 30 April 2021
Broadcast live and record in audio format of the Ordinary general meeting and Extraordinary General Meeting of April 28, 2021 (in French) 28 April 2021
U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma 27 April 2021
Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment 23 April 2021
U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension 22 April 2021
Nicox Provides First Quarter 2021 Business Update and Financial Highlights 19 April 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL 16 April 2021
Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021 13 April 2021
Nicox Ordinary and Extraordinary General Meetings of April 14, 2021 26 March 2021
Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone 23 March 2021
Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings 5 March 2021
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial 4 March 2021
Nicox Announces 2020 Financial Results and 2021 Key Milestones March 1, 2021
Nicox to Participate in Financial and Pharmaceutical Industry Events in H1 2021 25 February 2021
Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma 15 February 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SOUTH KOREA 9 February 2021
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021 29 January 2021
Nicox Analyst Coverage Initiated by Edison Investment Research 22 January 2021
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights 20 January 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico 6 January 2021
Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021 5 January 2021

2020

Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China 30 December 2020
Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia 22 December 2020
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis 15 December 2020
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment 11 December 2020
Nicox Analyst Coverage Initiated by Kepler Cheuvreux 25 November 2020
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® in Argentina 23 November 2020
Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma 10 November 2020
Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039 29 October 2020
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial 26 October 2020
Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents 23 October 2020
Nicox Announces Third Quarter 2020 Business Update and Financial Highlights 20 October 2020
BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIES 24 September 2020
Nicox’s ZERVIATE Receives IND Approval in China 22 September 2020
Nicox Announces Senior Management Change 18 September 2020
Nicox First Half 2020 Financial Results and Business Update 10 September 2020
Nicox Partners ZERVIATE™ in the Gulf and Arab Markets 12 August 2020
Nicox: Implementation of a liquidity contract with Kepler Cheuvreux 05 August 2020
Nicox Negotiating €2 million Non-Dilutive Loans Guaranteed by the French State 05 August 2020
Nicox Receives €5 Million Upon Closing of VISUfarma Divestment 31 July 2020
Nicox Second Quarter 2020 Business Update and Financial Highlights 17 July 2020
Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma 15 July 2020
Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding 10 July 2020
Nicox Partner Ocumension Completes Successful Hong Kong IPO at an approximately US$1,090 Million Valuation 10 July 2020
Nicox to Host Key Opinion Leader Call on NCX 470 for the Treatment of Glaucoma 18 June 2020
Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma 02 June 2020
Nicox First Quarter 2020 Business Update and Financial Highlights 17 April 2020
Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA 08 April 2020
Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease 02 April 2020
Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States 31 March 2020
Nicox Updates on ZERVIATE Progress in China and Expands the Countries of its Agreement with Ocumension Therapeutics 11 March 2020
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement 11 March 2020
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan 09 March 2020
Nicox Announces 2019 Financial Results and 2020 Key Milestones 06 March 2020
Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma 05 March 2020
Nicox Receives Formulation Patent Extending NCX 470 U.S. Patent Coverage to 2039 03 February 2020
Nicox Fourth Quarter 2019 Business Update and Financial Highlights 21 January 2020
Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina 16 January 2020
Nicox’s Partner Secures Approval of VYZULTA in Mexico 13 January 2020

2019

Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease 19 December 2019
Nicox Draws Down Last Tranche from Bond Financing Agreement with Kreos Capital to Support Key Development Programs 17 December 2019
Nicox signs agreement for ZERVIATE in South Korea 06 December 2019
Nicox Raises €12.5 Million to Advance NCX 470 into Phase 3 in Glaucoma 18 November 2019
Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma 22 October 2019
Nicox: Third Quarter 2019 Business Update and Financial Highlights 16 October 2019
Nicox Amends Bond Financing Agreement with Kreos and Draws Down Additional €4 Million 10 October 2019
Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost 02 October 2019
Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019 27 September 2019
Nicox: First Half 2019 Financial Results and Business Update 17 September 2019
Nicox: Second Quarter 2019 Business Update and Financial Highlights 17 July 2019
Nicox Announces Completion of Enrollment in NCX 470 Phase 2 Clinical Study with Top-Line Results on Track for Early 4Q 2019 16 July 2019
Nicox Receives $3 Million Milestone Payment from Eyevance for ZERVIATE in the U.S. 09 July 2019
Nicox signs agreement for NCX 4251 in China with Ocumension Therapeutics for up to €12 million in milestones plus royalties 02 July 2019
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019 06 May 2019
Nicox Presents First Data on Promising New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at the ARVO 2019 Annual Meeting 03 May 2019
Nicox First Quarter 2019 Business Update and Financial Highlights 18 April 2019
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis 19 March 2019
Nicox Poster Presentation at AGS 2019 Annual Meeting Discloses Preclinical Data for NCX 4251, a Novel Blepharitis Therapy 18 March 2019
Nicox signs agreement for ZERVIATE in China for up to €17 million in milestone payments plus royalties 15 March 2019
Nicox Announces Presentations at Upcoming Scientific Conferences 12 March 2019
Nicox Announces 2018 Financial Results and 2019 Milestones 06 March 2019
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis 29 January 2019
Nicox Establishes High-Profile Glaucoma Clinical Advisory Board 28 January 2019
Nicox extends cash runway beyond 2020 with bond financing from Kreos Capital of up to €20 million 25 January 2019
Nicox Fourth Quarter 2018 Business Update and Financial Highlights 17 January 2019

2018

Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations 21 December 2018
Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market 17 December 2018
Nicox Postpones NASDAQ Listing Due to Market Volatility 30 October 2018
Nicox Third Quarter 2018 Business Update and Financial Highlights 17 October 2018
Nicox and Fera Pharmaceuticals to Focus on a Rare Disease Indication for Naproxcinod 27 September 2018
Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States 06 September 2018
Nicox First Half 2018 Financial Results and Business Update 06 September 2018
Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension 02 August 2018
Nicox Second Quarter 2018 Business Update and Financial Highlights 17 July 2018
icox Highlights Recent Progress with Key Programs and Activities 29 June 2018
Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals 06 June 2018
Nicox Provides First Quarter 2018 Business and Financial Results 04 May 2018
Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018 03 May 2018
Nicox: Opening of U.S. Development Office in Research Triangle Park, North Carolina 25 April 2018
Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA 14 March 2018
Nicox provides 2018 Outlook and 2017 Estimated Financial Results 06 March 2018
Nicox Appoints Tomas Navratil, Ph.D., as Head of Development 03 January 2018

2017

Nicox Recaps 2017 Achievements, Provides Update on Commercial Availability of VYZULTA and Outlines 2018 Activities 19 December 2017
Nicox Highlights VYZULTA approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives 03 November 2017
BAUSCH + LOMB AND NICOX ANNOUNCE FDA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% 02 November 2017
Nicox Provides Third Quarter 2017 Business Update and Cash Position 24 October 2017
Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma 10 October 2017
Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATE in the United States 21 September 2017
Nicox first half 2017 business and financial update 08 September 2017
Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024% 18 August 2017
Nicox announces €26.25 million financing 15 August 2017
Press Release concerning latanoprostene bunod ophthalmic solution, 0.024% 08 August 2017
Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Aciex shareholders following the US FDA’s approval of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24%. 08 June 2017
Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24% 31 May 2017
Mrs. Lauren P. Silvernail appointed to Nicox Board of Directors 17 May 2017
Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017 09 May 2017
Nicox first quarter 2017 business update and cash position 27 April 2017
Nicox announces PDUFA date for ZERVIATE NDA 11 April 2017
Nicox: Business Update and 2016 Financial Results 31 March 2017
Bausch + Lomb and Nicox announce PDUFA date for novel glaucoma candidate latanoprostene bunod 20 March 2017
Nicox resubmits AC-170 (ZERVIATE1) NDA to the U.S. FDA 09 March 2017
Bausch + Lomb and Nicox resubmit US New Drug Application for novel glaucoma candidate latanoprostene bunod 27 February 2017
Nicox announces the presentation of NCX 667 scientific data at AOPT 2017 21 February 2017
Nicox provides clinical and regulatory update for NCX 4251 in blepharitis 05 January 2017

Cookies

By continuing to use this website, you agree to our Cookie Policy.